Celator Pharmaceuticals Inc. CEO Scott Jackson told BioWorld Today his firm has taken “the first step – it’s a huge step, but it’s the first step – toward becoming a new foundation of care” in high-risk (secondary) acute myeloid leukemia with Vyxeos, a liposomal form of cytarabine and daunorubicin.